Navigation Links
Bavarian Nordic Receives $25 Million Milestone Payment From HHS for Fulfilling Contract Milestones
Date:11/30/2007

WASHINGTON DC, November 30 /PRNewswire-FirstCall/ -- Bavarian Nordic has received permission from the Department of Health and Human Services (HHS) to invoice a milestone payment of $25 million as allowed under the RFP-3 contract* to manufacture and deliver 20 million doses of the company's, IMVAMUNE(R) next-generation smallpox vaccine candidate. HHS granted permission because the company fulfilled a number of significant milestones in the contract. The income will be recognised as revenue in the company's financial statements for 2007.

Anders Hedegaard, President & CEO of Bavarian Nordic, said, "We are very satisfied that we have fulfilled another significant milestone as agreed with the Department of Health and Human Services. With the already received and future payments, we have created a solid financial base for our further development."

In October 2007, Bavarian Nordic received an advance payment of $50 million from HHS as allowed under the contract. In addition to this amount and the current milestone payment, the company expects to receive an additional milestone payment of $25 million in 2007.

About the smallpox vaccine contract

In June 2007, HHS awarded Bavarian Nordic a BioShield contract to manufacture and deliver IMVAMUNE(R), a next-generation smallpox vaccine candidate to the strategic national stockpile. The contract calls for the registration of IMVAMUNE(R) as a safe and effective smallpox vaccine in healthy people, but in the event of a smallpox outbreak the vaccine would be recommended to protect people who have weakened immune systems.(1)

The five-year contract is valued at more than $500 million, with an option that if exercised, extends the value to $1.6 billion and the performance period of the contract. The contract option would allow the government to procure up to an additional 60 million doses of IMVAMUNE(R) and support additional clinical studies for extending the license to include the HIV-infected, pediatric, and geriatric populations.

Bavarian Nordic's contract is the first next-generation, or completely new product procured by HHS under the BioShield program. It is also is the first contract where HHS has utilized all of its existing and newly-acquired payment authorities (Advance Payment, Milestone Advance Payment, and Performance Based Payment) as granted under the Project BioShield Act (2004), The Pandemic and All-Hazards Preparedness Act (2006), and the FAR subpart 32.10.

Notes/References

* This project has been funded in whole with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C.

(1) http://www.hhs.gov/news/press/2007pres/06/pr20070604a.html

About Bavarian Nordic

Bavarian Nordic, headquartered in Denmark, is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer.

In the U.S., Bavarian Nordic operates subsidiary companies, BN ImmunoTherapeutics, in Mountain View, California developing vaccines against cancers, and Bavarian Nordic Inc. in Washington, D.C. focused on business development, marketing, and government relations for the Bavarian Nordic Group. For more information on Bavarian Nordic visit: http://www.bavarian-nordic.com

"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995": Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate
2. Nordic Naturals Introduces Ultimate Omega 500 - Their Best Selling Formula Now Available in a Smaller Size Soft Gel!
3. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
4. DaVita Receives Civil Complaint
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
7. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
8. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
11. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology: